Maintaining a hematocrit below 45% is the objective in managing patients with low-risk polycythemia vera. Mojtaba Akhtari, MD, and participants explore therapeutic approaches.
Patients With Polycythemia Vera Eligible for Treatment Injection
During a live event, Raajit K. Rampal, MD, PhD, discussed ropeginterferon's potential to reduce JAK2 allele burden in low-risk polycythemia vera.
During a live event, Raajit K. Rampal, MD, PhD, discusses managing a patient with low-risk polycythemia vera.
During a live event, Mojtaba Akhtari, MD, discussed trials studying patients with high-risk polycythemia vera.
During a live event, Mojtaba Akhtari, MD, discussed the goals and treatment approach for patients with low-risk polycythemia vera.
Douglas A. Tremblay, MD, discusses the importance of quality-of-life data from treating patients with polycythemia vera with ropeginterferon alfa-2b-njft.
Douglas A. Tremblay, MD, discusses the data showing disease-modifying potential of ropeginterferon alfa-2b-njft in patients with polycythemia vera.
Douglas A. Tremblay, MD, discusses the long-term data supporting ropeginterferon alfa-2b-njft as treatment in patients with polycythemia vera.